Tiger Brokers

Bayer New Stroke Drug Can Withstand Competition

Dow Jones
Nov 10

1405 GMT - Bayer's new stroke drug looks well positioned to withstand competition, according to analysts at Bank of America. The drug asundexian is likely to benefit from good adoption and could generate annual sales of 3 billion euros at its peak, the bank estimates. Rivals Bristol Myers Squibb and Johnson & Johnson are working together on a competitor medicine candidate, milvexian. Upcoming data on milvexian could prompt Bank of America to revise its asundexian estimate, but most scenarios it is contemplating would result in upgrades. Even if milvexian ends up working in secondary stroke prevention and stroke prevention in atrial fibrillation, consensus estimates for asundexian peak sales of 2 billion euros would face limited risk, the analysts say. Bayer shares rise 0.2%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10